Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health step therapy Coverage Update | …
    Ask Trek AI about this page
    CurrentIndependent HealthPolicy N/A

    Step therapy protocols for select drugs

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy requirements for specific drugs on Independent Health Medicare Advantage Part D formularies; applies to prescribers and pharmacy prior authorization reviewers for affected Medicare Advantage members.

    Policy Summary
    PayerIndependent Health
    PolicyStep therapy protocols for select drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must document prior use of the required agent(s) listed for each product to obtain coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≈15products listed with step requirements
    Medicare Part Dformulary type covered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1required prior agent in most criteria

    Coverage Criteria — Product-specific Step Therapy

    Aliskiren

    Covered when the following prior therapy has been tried

    Aliskiren 300 mg: Requires prior use of an angiotensin-II receptor blocker (ARB)prior ARB trial

    applies to aliskiren fumarate tablet 300 mg oral

    Aripiprazole formulations

    Formulation-sequencing requirements

    Aripiprazole ODT: Requires prior use of aripiprazole oral solutionprior oral solution trial

    applies to aripiprazole orally-disintegrating tablet (ODT)

    Aripiprazole film: Requires prior use of aripiprazole ODTprior ODT trial

    applies to aripiprazole oral film products (e.g., OPIPZA FILM)

    EUCRISA

    Topical therapy sequencing

    EUCRISA: Requires prior use of either a topical corticosteroid or a topical calcineurin inhibitortrial of topical steroid or calcineurin inhibitor

    applies to EUCRISA ointment

    Febuxostat

    Gout urate-lowering therapy sequencing

    Febuxostat: Requires prior use of allopurinolprior allopurinol trial

    applies to febuxostat tablets (e.g., 40 mg, 80 mg)

    SYMPAZAN

    Clobazam sequencing for clobazam-containing product

    SYMPAZAN films: Requires prior use of clobazam oral suspensionprior clobazam suspension trial

    applies to SYMPAZAN film products

    Trelstar MixJect

    GnRH analog sequencing

    Trelstar MixJect: Requires prior use of Lupron Depotprior Lupron Depot trial

    applies to TRELSTAR MixJect suspension formulations (reconstituted)

    Versacloz / Doxercalciferol

    Clozapine and vitamin D analog sequencing

    Versacloz suspension: Requires prior use of clozapine orally-disintegrating tablet (ODT)prior clozapine ODT trial

    applies to VERSACLOZ suspension 50 mg/mL oral

    Doxercalciferol 2.5 mcg: Requires prior use of calcitriolprior calcitriol trial

    applies to doxercalciferol capsule 2.5 mcg oral

    The formulary listed in this document applies to Independent Health Medicare Advantage Part D formularies and is current as of 3/1/2026. The formulary may change at any time; members will receive notice when changes are necessary.

    Actions Required from Prescribers and Reviewers

    Prior Authorization

    Step therapy requirement

    Step therapy protocols apply for drugs on the Medicare Advantage Part D formularies listed; prescribers must document prior use of required agents per the listed criteria to obtain coverage.

    • Documentation must show trial and inadequate response, intolerance, or contraindication to the required prior agent to advance to the requested product.
    Step Therapy

    Product-specific step requirements

    Specific products in this list require documented prior trials of the agent(s) named in each product’s coverage criteria; see the coverage module for each product for the exact prior-agent requirement.

    • Must trial the specified prior agent(s) listed for each product before coverage of the requested product is approved.

    Initial Therapy Requirements

    Initial therapy requirements

    Initial coverage requires documented trial and failure or contraindication to the required prior agent(s) listed per product.

    Aliskiren 300 mg initial: Trial of an angiotensin-II receptor blocker (ARB) required before covering aliskiren 300 mgprior ARB trial documented

    see product-specific criteria

    Aripiprazole ODT/film initial: Sequencing: aripiprazole oral solution → aripiprazole ODT → aripiprazole oral film as applicabledocumented prior formulation trial

    see product-specific criteria

    EUCRISA initial: Trial of a topical corticosteroid OR a topical calcineurin inhibitor required before covering EUCRISA

    Step Therapy Table — Required Prior Agents

    ProductRequired prior agent(s) / sequenceNotes
    Aliskiren fumarate tablet 300 mg oral
    Angiotensin-II receptor blocker (ARB)
    Requires prior ARB trial before coverage
    Aripiprazole tablet dispersible 10 mg; Aripiprazole tablet dispersible 15 mg; OPIPZA FILM (as applicable)
    Aripiprazole oral solution → Aripiprazole ODT → Aripiprazole oral film (films require prior ODT; ODT requires prior oral solution)
    Formulation-specific sequencing; ODT = orally-disintegrating tablet
    EUCRISA ointment 2%
    Topical corticosteroid OR topical calcineurin inhibitor
    Either topical steroid or topical calcineurin inhibitor must be tried first
    Febuxostat tablet 40 mg; Febuxostat tablet 80 mg
    Allopurinol
    Allopurinol must be tried prior to febuxostat
    SYMPAZAN FILM (5 mg, 10 mg, 20 mg)
    Clobazam oral suspension
    Clobazam suspension required prior to Sympazan films
    TRELSTAR MIXJECT suspension (reconstituted 3.75 mg, 11.25 mg, 22.5 mg)
    Lupron Depot
    Lupron Depot must be tried before Trelstar MixJect formulations
    VERSACLOZ suspension 50 mg/mL oral
    Clozapine orally-disintegrating tablet (ODT)
    Clozapine ODT required prior to Versacloz suspension
    Doxercalciferol capsule 2.5 mcg (also 0.5 mcg, 1 mcg listed)
    Calcitriol
    Calcitriol must be tried prior to doxercalciferol 2.5 mcg

    Definitions and Abbreviations

    inv-20: Orally-disintegrating tablet — ODT definition / key-value
    TermOrally-disintegrating tablet (ODT)
    DefinitionA tablet formulation designed to disintegrate in the mouth (ODT)
    Policy implicationAripiprazole ODT requires prior use of aripiprazole oral solution before coverage is approved
    Applies toAripiprazole tablet dispersible 10 mg and 15 mg (ODT)
    Sequencing noteAripiprazole oral films require prior trial of aripiprazole ODT

    Background — Step Therapy Rationale

    Step therapy is a utilization management technique that requires a trial of a preferred or lower-cost medication before coverage of an alternative agent will be approved. This document lists the step requirements associated with the Medicare Advantage Part D formularies and explains that prescribers must document prior trials of the required agents to obtain coverage; if the preferred agent is ineffective, intolerable, or contraindicated, the next-step product may be covered.

    Policy Summary
    PayerIndependent Health
    PolicyStep therapy protocols for select drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must document prior use of the required agent(s) listed for each product to obtain coverage.
    SourceLink
    On This Page
    Coverage Criteria — Product-specific Step TherapyActions Required from Prescribers and ReviewersInitial Therapy RequirementsStep Therapy Table — Required Prior AgentsDefinitions and AbbreviationsBackground — Step Therapy Rationale
    Note

    Medicare Member Services contact

    For questions about coverage or step therapy requirements, contact Medicare Member Services at 1-800-665-1502 (TTY 711). Member service hours: Oct 1–Mar 31: Monday–Sunday 8 a.m.–8 p.m.; Apr 1–Sep 30: Monday–Friday 8 a.m.–8 p.m.

    Prior Authorization

    Aliskiren 300 mg: prior ARB trial required

    Coverage for aliskiren fumarate 300 mg oral requires prior use of an angiotensin‑II receptor blocker (ARB); prescribers must document a prior ARB trial.

    Prior Authorization

    Aripiprazole formulation sequencing

    Aripiprazole formulation sequencing must be followed: orally‑disintegrating tablets (ODT) require prior use of aripiprazole oral solution; aripiprazole oral films require prior use of aripiprazole ODT. Document the appropriate prior formulation trial.

    Prior Authorization

    EUCRISA: prior topical therapy required

    EUCRISA (ointment 2%) requires prior use of either a topical corticosteroid or a topical calcineurin inhibitor; prescribers must document trial of one of these topical therapies.

    Prior Authorization

    Febuxostat: prior allopurinol trial required

    Febuxostat (including 40 mg and 80 mg listings) requires prior use of allopurinol; document a prior allopurinol trial before requesting febuxostat.

    Prior Authorization

    SYMPAZAN: prior clobazam suspension required

    SYMPAZAN film products require prior use of clobazam oral suspension; documentation of a prior clobazam suspension trial is required for coverage.

    Prior Authorization

    Trelstar MixJect: prior Lupron Depot required

    TRELSTAR MixJect formulations listed require prior use of Lupron Depot; document a prior Lupron Depot trial for authorization.

    Prior Authorization

    Clozapine/doxercalciferol sequencing

    VERSACLOZ suspension requires prior use of clozapine orally‑disintegrating tablet (ODT); separately, doxercalciferol 2.5 mcg requires prior use of calcitriol. Providers must document the applicable prior-agent trial.

    documented topical therapy trial

    see product-specific criteria

    Febuxostat initial: Allopurinol must be tried firstprior allopurinol trial documented

    see product-specific criteria

    SYMPAZAN initial: Clobazam oral suspension must be tried firstprior clobazam suspension trial documented

    see product-specific criteria

    Trelstar initial: Lupron Depot must be tried firstprior Lupron Depot trial documented

    see product-specific criteria

    Versacloz initial: Clozapine ODT must be tried firstprior clozapine ODT trial documented

    see product-specific criteria

    Doxercalciferol 2.5 mcg initial: Calcitriol must be tried firstprior calcitriol trial documented

    see product-specific criteria